<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
                      "http://www.w3.org/TR/html4/strict.dtd">
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta name="generator" content="hypermail 2.1.5, see http://www.hypermail.org/">
<title>Extropians: Re: Performance enhancement with selegiline</title>
<meta name="Author" content="Rafal Smigrodzki (rms2g@virginia.edu)">
<meta name="Subject" content="Re: Performance enhancement with selegiline">
<meta name="Date" content="2003-02-08">
<style type="text/css">
body {color: black; background: #ffffff}
h1.center {text-align: center}
div.center {text-align: center}
</style>
</head>
<body>
<h1>Re: Performance enhancement with selegiline</h1>
<!-- received="Sat Feb  8 18:26:30 2003" -->
<!-- isoreceived="20030209012630" -->
<!-- sent="Sat, 8 Feb 2003 20:26:28 -0500" -->
<!-- isosent="20030209012628" -->
<!-- name="Rafal Smigrodzki" -->
<!-- email="rms2g@virginia.edu" -->
<!-- subject="Re: Performance enhancement with selegiline" -->
<!-- id="00cb01c2cfda$45955570$6401a8c0@dimension" -->
<!-- charset="iso-8859-1" -->
<!-- inreplyto="019601c2cf67$e9823180$e35f87d8@pavilion" -->
<!-- expires="-1" -->
<p>
<strong>From:</strong> Rafal Smigrodzki (<a href="mailto:rms2g@virginia.edu?Subject=Re:%20Performance%20enhancement%20with%20selegiline"><em>rms2g@virginia.edu</em></a>)<br>
<strong>Date:</strong> Sat Feb 08 2003 - 18:26:28 MST
</p>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2354.html">Eliezer S. Yudkowsky: "Debunking meatspace (was: I am the Google)"</a>
<ul>
<li><strong>Previous message:</strong> <a href="2352.html">Damien Broderick: "RE: I am the Google"</a>
<li><strong>In reply to:</strong> <a href="2313.html">gts: "Re: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="../0301/1641.html">Alex Ramonsky: "Re: Performance enhancement with donepezil"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2353">[ date ]</a>
<a href="index.html#2353">[ thread ]</a>
<a href="subject.html#2353">[ subject ]</a>
<a href="author.html#2353">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<hr>
<!-- body="start" -->
<p>
I know of at least five compounds (calcium blockers, iron chelators, and
<br>
other things I already forgot about) that worked in the same model, but
<br>
failed in clinical trials. The Stroke Institute in Pittsburgh is always
<br>
running two-three trials simultaneously, but so far nothing panned out.
<br>
<p>Rafal
<br>
<p>----- Original Message -----
<br>
From: &quot;gts&quot; &lt;<a href="mailto:gts_2000@yahoo.com?Subject=Re:%20Performance%20enhancement%20with%20selegiline">gts_2000@yahoo.com</a>&gt;
<br>
To: &quot;gts&quot; &lt;<a href="mailto:gts_2000@yahoo.com?Subject=Re:%20Performance%20enhancement%20with%20selegiline">gts_2000@yahoo.com</a>&gt;; &lt;<a href="mailto:extropians@extropy.org?Subject=Re:%20Performance%20enhancement%20with%20selegiline">extropians@extropy.org</a>&gt;
<br>
Sent: Saturday, February 08, 2003 6:47 AM
<br>
Subject: Re: Performance enhancement with selegiline
<br>
<p><p><em>&gt; Here is more evidence of neuroprotection by selegiline/deprenyl:
</em><br>
<em>&gt;
</em><br>
<em>&gt; This is evidence that selegiline protects neurons from death due to from
</em><br>
<em>&gt; temporary lack of oxygen (hypoxia) as in stroke (ischemia).
</em><br>
<em>&gt;
</em><br>
<em>&gt; ABSTRACT
</em><br>
<em>&gt; L-deprenyl reduces brain damage in rats exposed to transient
</em><br>
<em>&gt; hypoxia-ischemia.
</em><br>
<em>&gt;
</em><br>
<em>&gt; Stroke 1995 Oct;26(10):1883-7    (ISSN: 0039-2499)
</em><br>
<em>&gt; Knollema S; Aukema W; Hom H; Korf J; ter Horst GJ
</em><br>
<em>&gt; University of Groningen, Department of Biological Psychiatry, The
</em><br>
<em>&gt; Netherlands.
</em><br>
<em>&gt; BACKGROUND AND PURPOSE: L-Deprenyl (Selegiline) protects animal brains
</em><br>
<em>&gt; against toxic substances such as 1-methyl-1,2,3,6-tetrahydropyridine and
</em><br>
<em>&gt; 6-hydroxydopamine. Experiments were conducted to test whether L-deprenyl
</em><br>
<em>&gt; prevents or reduces cerebral damage in a transient hypoxia/ischemia rat
</em><br>
<em>&gt; model. METHODS: Rats were treated for 14 days with 2 mg/kg and 10 mg/kg
</em><br>
<em>&gt; L-deprenyl or saline. After surgery a 20-minute hypoxia/ischemia period
</em><br>
was
<br>
<em>&gt; induced by simultaneous occlusion of the left common carotid artery and
</em><br>
<em>&gt; reduction of the percentage of oxygen in the gas mixture to 10%. Rats were
</em><br>
<em>&gt; killed 24 hours later. Silver staining was used to reveal damage in
</em><br>
several
<br>
<em>&gt; brain regions. RESULTS: In the brain, both L-deprenyl dosages reduced
</em><br>
damage
<br>
<em>&gt; up to 78% compared with the controls. Total brain damage was decreased
</em><br>
from
<br>
<em>&gt; 23%-31% to 5%-9% with the L-deprenyl treatment (2 mg/kg: F1.13 = 6.956, P
</em><br>
&lt;
<br>
<em>&gt; .05; 10 mg/kg: F1.13 = 5.731, P &lt; .05). In the striatum, significant
</em><br>
<em>&gt; treatment effects were found between both the L-deprenyl groups (2 mg/kg
</em><br>
and
<br>
<em>&gt; 10 mg/kg, respectively) and the saline group (F1.13 = 14.870, P &lt; .005;
</em><br>
and
<br>
<em>&gt; F1.13 = 8.937, P = .01; respectively). In the thalamus, significant
</em><br>
<em>&gt; treatment effects were seen in the 2-mg/kg L-deprenyl group (F1.13 =
</em><br>
11.638,
<br>
<em>&gt; P &lt; .005) and the 10-mg/kg group (F1.13 = 8.347, P &lt; .05) compared with
</em><br>
the
<br>
<em>&gt; control group. No significant damage decrease was seen in the hippocampus
</em><br>
<em>&gt; and the cortex. CONCLUSIONS: The results show that L-deprenyl is effective
</em><br>
<em>&gt; as a prophylactic treatment for brain tissue when it is administered
</em><br>
before
<br>
<em>&gt; hypoxia/ischemia. Mechanisms responsible for the observed protection
</em><br>
remain
<br>
<em>&gt; unclear. The regional differences in damage, however, are in accordance
</em><br>
with
<br>
<em>&gt; the reported regional increase in superoxide dismutase and catalase
</em><br>
<em>&gt; activities after L-deprenyl treatment, suggesting the involvement of free
</em><br>
<em>&gt; radicals and scavenger enzymes.
</em><br>
<em>&gt;
</em><br>
<em>&gt;
</em><br>
<!-- body="end" -->
<hr>
<ul>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2354.html">Eliezer S. Yudkowsky: "Debunking meatspace (was: I am the Google)"</a>
<li><strong>Previous message:</strong> <a href="2352.html">Damien Broderick: "RE: I am the Google"</a>
<li><strong>In reply to:</strong> <a href="2313.html">gts: "Re: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="../0301/1641.html">Alex Ramonsky: "Re: Performance enhancement with donepezil"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2353">[ date ]</a>
<a href="index.html#2353">[ thread ]</a>
<a href="subject.html#2353">[ subject ]</a>
<a href="author.html#2353">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<!-- trailer="footer" -->
<hr>
<p><small><em>
This archive was generated by <a href="http://www.hypermail.org/">hypermail 2.1.5</a> 
: Sat Feb 08 2003 - 18:28:39 MST
</em></small></p>
</body>
</html>
